UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Crenolanib is a selective type I pan-FLT3 inhibitor

Proceedings of the National Academy of Sciences - PNAS, 2014-04, Vol.111 (14), p.5319-5324

2014

Volltextzugriff (PDF)

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Blood, 2013-04, Vol.121 (16), p.3165-3171

2013

Volltextzugriff (PDF)

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397

Cancer discovery, 2015-06, Vol.5 (6), p.668-679

2015

Volltextzugriff (PDF)

Mobilization of hematopoietic stem cells into the peripheral blood

Expert Review of Hematology, 2009-12, Vol.2 (6), p.717-733

2009

Volltextzugriff (PDF)

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Blood, 2013-11, Vol.122 (21), p.3938-3938

2013

Volltextzugriff (PDF)

Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants

Blood, 2011-11, Vol.118 (21), p.930-930

2011

Volltextzugriff (PDF)

PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro

Blood, 2011-11, Vol.118 (21), p.764-764

2011

Volltextzugriff (PDF)

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Blood, 2012-11, Vol.120 (21), p.674-674

2012

Volltextzugriff (PDF)

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Blood, 2012-11, Vol.120 (21), p.141-141

2012

Volltextzugriff (PDF)

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy

Blood, 2011-11, Vol.118 (21), p.3752-3752

2011

Volltextzugriff (PDF)

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia

Blood, 2011-11, Vol.118 (21), p.937-937

2011

Volltextzugriff (PDF)

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Blood, 2011-11, Vol.118 (21), p.2611-2611

2011

Volltextzugriff (PDF)

Azido and Tetrazolo 1,2,4,5‐Tetrazine N‐Oxides

Angewandte Chemie (International ed.), 2017-03, Vol.56 (13), p.3575-3578

International ed. in English, 2017

Volltextzugriff (PDF)

Energetic Trinitro- and Fluorodinitroethyl Ethers of 1,2,4,5-Tetrazines

Angewandte Chemie (International ed.), 2016-07, Vol.55 (30), p.8666-8669

International ed. in English, 2016

Volltextzugriff (PDF)

Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec

Molecular therapy. Methods & clinical development, 2023-09, Vol.30, p.474-483

2023

Volltextzugriff (PDF)

The United States National Cancer Institute’s Coordinated Research Effort on Tobacco Use as a Major Cause of Morbidity and Mortality among People with HIV

Nicotine & tobacco research, 2021-01, Vol.23 (2), p.407-410

2021

Volltextzugriff (PDF)

COVID-19 Challenges Confronted by Smoking Cessation Clinical Trials for People Living With HIV: The Experience of Grantees of the US National Cancer Institute

Nicotine & tobacco research, 2021-09, Vol.23 (9), p.1629-1632

2021

Volltextzugriff (PDF)

Validity of ICD‐10‐CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies

Pharmacoepidemiology and drug safety, 2021-07, Vol.30 (7), p.899-909

2021

Volltextzugriff (PDF)

Shariant platform: Enabling evidence sharing across Australian clinical genetic-testing laboratories to support variant interpretation

American journal of human genetics, 2022-11, Vol.109 (11), p.1960-1973

2022

Volltextzugriff (PDF)

Girls and Boys Born before 28 Weeks Gestation: Risks of Cognitive, Behavioral, and Neurologic Outcomes at Age 10 Years

The Journal of pediatrics, 2016-06, Vol.173, p.69-75.e1

2016

Volltextzugriff (PDF)

Cerebral Palsy and Motor Impairment After Extreme Prematurity: Prediction of Diagnoses at Ages 2 and 10 Years

The Journal of pediatrics, 2024-08, Vol.271, p.114037, Article 114037

2024

Volltextzugriff (PDF)

Co-occurrence and Severity of Neurodevelopmental Burden (Cognitive Impairment, Cerebral Palsy, Autism Spectrum Disorder, and Epilepsy) at Age Ten Years in Children Born Extremely Preterm

Pediatric neurology, 2018-02, Vol.79, p.45-52

2018

Volltextzugriff (PDF)

Crystal structures of the three closely related compounds: bis[(1 H -tetrazol-5-yl)methyl]nitramide, triaminoguanidinium 5-({[(1 H -tetrazol-5-yl)methyl](nitro)amino}methyl)tetrazol-1-ide, and diammonium bis[(tetrazol-1-id-5-yl)methyl]nitramide monohydrate

Acta crystallographica. Section E, Crystallographic communications, 2017-07, Vol.73 (7), p.1056-1061

2017

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(32)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(16)
Humans
(12)
Chemistry
(4)
Female
(4)
Male
(4)
Pediatrics
(4)
Tetrazole
(4)
Animals
(3)
Cell Line, Tumor
(3)
Energetic Materials
(3)
Fms-Like Tyrosine Kinase 3 - Chemistry
(3)
Fms-Like Tyrosine Kinase 3 - Genetics
(3)
Hematology
(3)
Medicine, Research & Experimental
(3)
Mice
(3)
Oncology
(3)
Oxidation
(3)
Physical Sciences
(3)
Public, Environmental & Occupational Health
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Crenolanib is a selective type I pan-FLT3 inhibitor

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397

Mobilization of hematopoietic stem cells into the peripheral blood

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants

PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Azido and Tetrazolo 1,2,4,5‐Tetrazine N‐Oxides

Energetic Trinitro- and Fluorodinitroethyl Ethers of 1,2,4,5-Tetrazines

Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial

Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec

The United States National Cancer Institute’s Coordinated Research Effort on Tobacco Use as a Major Cause of Morbidity and Mortality among People with HIV

COVID-19 Challenges Confronted by Smoking Cessation Clinical Trials for People Living With HIV: The Experience of Grantees of the US National Cancer Institute

ATRAID regulates the action of nitrogen-containing bisphosphonates on bone

Validity of ICD‐10‐CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies

Shariant platform: Enabling evidence sharing across Australian clinical genetic-testing laboratories to support variant interpretation

Girls and Boys Born before 28 Weeks Gestation: Risks of Cognitive, Behavioral, and Neurologic Outcomes at Age 10 Years

Cerebral Palsy and Motor Impairment After Extreme Prematurity: Prediction of Diagnoses at Ages 2 and 10 Years

Co-occurrence and Severity of Neurodevelopmental Burden (Cognitive Impairment, Cerebral Palsy, Autism Spectrum Disorder, and Epilepsy) at Age Ten Years in Children Born Extremely Preterm

Crystal structures of the three closely related compounds: bis[(1 H -tetrazol-5-yl)methyl]nitramide, triaminoguanidinium 5-({[(1 H -tetrazol-5-yl)methyl](nitro)amino}methyl)tetrazol-1-ide, and diammonium bis[(tetrazol-1-id-5-yl)methyl]nitramide monohydrate

Suchergebnisse filtern